Neuropathic pruritus - 05/07/23
, Anusha Kambala, BS a, ∗, Xinzhong Dong, PhD a, b, c, dKey words : Pruritus, neuropathy, inflammation
Le texte complet de cet article est disponible en PDF.
Plan
| Supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health (to S.G.K. [grant K23AR077073-01A1]). |
|
| Disclosure of potential conflict of interest: S. G. Kwatra is an advisory board member and/or consultant for AbbVie, Aslan Pharmaceuticals, Arcutis Biotherapeutics, Celldex Therapeutics, Castle Biosciences, Galderma, Genzada Pharmaceuticals, Incyte Corporation, Johnson & Johnson, Leo Pharma, Novartis Pharmaceuticals Corporation, Pfizer, Regeneron Pharmaceuticals, and Sanofi and has served as an investigator for Galderma, Incyte, Pfizer, and Sanofi. X. Dong is a cofounder and consultant of Escient Pharmaceuticals. The remaining author declares no relevant conflicts of interest. |
Vol 152 - N° 1
P. 36-38 - juillet 2023 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
